CAS NO: | 147254-64-6 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Ranirestat (AS-3201) potent and orally activealdose reductase(AR)inhibitor withIC50s of 11 nM and 15 nM forrat lens ARandrecombinant human AR, respectively, and aKiof 0.38 nM forrecombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas[1][2]. | ||||||||||||||||
IC50& Target | IC50: 11 nM (Rat lens aldose reductase) and 15 nM (Recombinant humanaldose reductase)[1] | ||||||||||||||||
体外研究 (In Vitro) | Ranirestat concentration-dependently inhibits sorbitol accumulation in rat erythrocytes and sciatic nerves incubated in the high concentration (500 mg/dl) of glucose. The potency of Ranirestat inhibition of sorbitol accumulation is similar between rat erythrocytes and sciatic nerves with IC50values of 0.010 μM and 0.041 μM, respectively[1]. | ||||||||||||||||
体内研究 (In Vivo) | Ranirestat (0.03-1.0 mg/kg; oral administration; once daily; for 3 weeks; male STD-Wistar rats) treatment dose-dependently decreases the elevated sorbitol and fructose levels in the rat sciatic nerves without affecting blood glucose level. Ranirestat also improves the STZ-induced decrease in motor nerve conduction velocity (MNCV) in a dose-dependent manner[1].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 420.19 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C17H11BrFN3O4 | ||||||||||||||||
CAS 号 | 147254-64-6 | ||||||||||||||||
中文名称 | 雷尼司他 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(118.99 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|